Bioequivalence Assessment of Two Brands (Dong-Kwang $\textrm{Tramcinolone}^{(R)}$ vs. Wyeth Korea $\textrm{Ledercoat}^{(R)}$ 4 mg Tablets) of Triamcinolone in Healthy Male Human Volunteers

  • Kwon, Oh-Seung (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Heesoo Pyoa (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Jang, Moon-Sun (Toxicology Lab., Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology) ;
  • Chung, Youn-Bok (College of Pharmacy, Chungbuk National University)
  • Published : 2002.07.01

Abstract

The bioequivalence of two 4 mg triamcinolone tablets (Dong-Kwang $\textrm{Tramcinolone}^{(R)}$ vs. Wyeth Korea $\textrm{Ledercoat}^{(R)}$) was assesed in healthy male Korean volunteers after oral administration of 16 mh triamcinolone in a randomized crossover study. Blood samples were collected at specified time intervals, and plasma was analyzed for triamcinolone using a validated HPLC method. The pharmacokinetic parameters of $T_{max}$, $C_{max}$, $AUC_{0{\longrightarrow}last}$. $AUC_{0{\longrightarrow}imf}$, and $T_{1/2,\beta}$ were determined from plasma concentration-time profile of two formulations. The pharmacokinetic parameters were statistically compared to evaluate bioequivalence between two formulations, according to the United State or Korea Food and Drug Administration Guidelines. The analysis of variance did not show any signigicant difference between the two formulations and 90% confidence limits fell within the acceptable range (80-120%) for bioequivalence. Based on these data it was concluded that the two products showed comparable pharmacokinetic profiles and that the Dong-Kwang $\textrm{Tramcinolone}^{(R)}$ tablet is bioequivalent to the $\textrm{Ledercoat}^{(R)}$ tablet produced by Wyeth Korea.

Keywords